Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Satricabtagene autoleucel - CARsgen

Next Previous
X
Search
Drug Profile

Satricabtagene autoleucel - CARsgen

Alternative Names: 1-3 CT041 autologous CAR T-cell injection infusion; Anti-Claudin18.2-CAR-T cell therapy - CARsgen; CAR-CLD18 T cell therapy - CARsgen; CAR-CLDN18.2 T-Cells; Chimeric Antigen Receptor T cells targeting Claudin18.2; Claudin 18.2-CAR-T cell therapy - CARsgen; Claudin18.2 (CLDN18.2) CAR-T - CARsgen; Claudin18.2-redirected Autologous Cells - CARsgen; CLD18-CAR-T cell therapy - CARsgen; CLDN18.2 targeting CAR-T cell therapy - CARsgen; CT-041; CT041 autologous CAR T-cell injection

Latest Information Update: 22 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CARsgen
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Oesophageal cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastric cancer; Oesophageal cancer; Pancreatic cancer

Most Recent Events

  • 19 Aug 2024 Updated efficacy data from a phase I trial in Gastric cancer and Oesophageal cancer released by CARsgen Therapeutics
  • 31 May 2024 Updated efficacy and adverse event data from a phase I trial in Gastrointestinal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 05 Apr 2024 Updated efficacy and adverse events data from a phase I trial in Oesophageal cancer, Gastric cancer and Pancreatic cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top